MAMonika Augustyn

Monika Augustyn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monika Augustyn has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SELECTED BIOMARKERS IN SEPSIS: IL-6, sTREM-1 AND NEUTROPHIL CD64 - A LITERATURE REVIEW

    by Aleksander Midera, Kinga Popielarska, Klaudia Elżbieta Niwińska, Natalia Maria Leśniak, Anna Maria Zakrzewska, Julia Aleksandra Leśniak, Michał Borowski, Julia Agnieszka Michalak, Monika Augustyn

    Background: Sepsis is a life-threatening condition characterised by organ dysfunction caused by a dysregulated host response to infection and remains a major cause of morbidity and mortality worldwide. Early recognition is clinically challenging because initial symptoms are non-specific and commonly used inflammatory markers have limited diagnostic performance. Consequently, there is ongoing interest in biomarkers that enable faster and more accurate identification of sepsis. Aim: To discuss selected sepsis biomarkers: interleukin-6 (IL-6), soluble TREM-1 (sTREM-1), and neutrophil CD64 expression, with particular emphasis on biological mechanisms, clinical utility, and diagnostic limitations. Materials and methods: A narrative review of the literature was undertaken. Publications from 2016 to 2025 indexed in PubMed/MEDLINE, Scopus, and Google Scholar were analysed, including clinical studies, reviews, and meta-analyses. Evidence was assessed with respect to biological mechanisms, diagnostic and prognostic performance, and limitations of the biomarkers. Results: Neutrophil CD64 expression shows high specificity for bacterial infection and sepsis; however, routine use is constrained by limited assay standardisation and the absence of validated cut-off values. IL-6 rises very early and has prognostic value, correlating with the severity of organ dysfunction and mortality risk, but it has low specificity. sTREM-1 reflects activation of the TREM-1 axis and the intensity of the inflammatory response; however, its ability to distinguish sepsis from non-infectious SIRS is limited. Conclusions: None of the reviewed biomarkers should be used as a stand-alone diagnostic test. The greatest clinical value is likely to be achieved with a multiparametric approach that combines clinical assessment and organ dysfunction scores with biomarkers representing different stages of the immune response. This strategy may improve early recognition, risk stratification, and monitoring of sepsis.

  • Open Access

    ORAL MANIFESTATIONS OF AMYLOIDOSIS AS AN EARLY INDICATOR OF THE DISEASE - A LITERATURE REVIEW

    by Kinga Popielarska, Michał Borowski, Anna Maria Zakrzewska, Julia Aleksandra Leśniak, Natalia Maria Leśniak, Julia Agnieszka Michalak, Klaudia Elżbieta Niwińśka, Klaudia Martyna Patrzykąt, Aleksander Midera, Monika Augustyn

    Introduction and Purpose: Amyloidosis is a rare group of diseases characterized by the irreversible extracellular deposition of insoluble amyloid fibrils in various organs and tissues. Treatment should begin as early as possible, immediately following diagnosis. Therefore, clinicians should be aware of the disease’s characteristic features, including those visible in the oral cavity- which will be the focus of this article. While systemic manifestations are often emphasized, changes in the oral cavity can serve as early- and sometimes the first- indicators of the disease. The aim of this article is to present the most relevant and recent scientific reports from the past ten years regarding oral manifestations of amyloidosis, highlight their diagnostic value, and emphasize the role of the dental professionals in the multidisciplinary approach to early detection and patient care. Description of the State of Knowledge: Recent literature highlights a broad range of oral manifestations in amyloidosis, including macroglossia, nodular lesions, hemorrhagic changes, and chronic ulcers- some of which may appear without systemic symptoms. Histopathological biopsy with Congo red staining remains the gold standard for confirming amyloid deposits. Case reports increasingly show that oral findings can prompt systemic evaluation, leading to earlier diagnosis and management. This underscores the importance of dental professionals in recognizing subtle signs and initiating appropriate referrals. Conclusions: Oral signs of amyloidosis can be the first clue to a systemic disease. Recognizing the type and location of lesions helps assess whether the disease is localized or systemic. Early diagnosis may improve outcomes- and in some cases, even save the patient’s life.

  • Open Access

    SLEEP DISORDERS AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: A COMPREHENSIVE REVIEW

    by Julia Aleksandra Leśniak, Natalia Maria Leśniak, Klaudia Martyna Patrzykąt, Anna Maria Zakrzewska, Aleksander Midera, Michał Borowski, Klaudia Elżbieta Niwińska, Julia Agnieszka Michalak, Monika Augustyn, Kinga Popielarska, et al.

    Background. Sleep disorders represent a heterogeneous group of conditions that impair sleep quality, duration, and architecture, leading to significant daytime dysfunction and increased global morbidity. Epidemiological data indicate that approximately 30–40% of adults experience sleep disturbances, including insomnia and obstructive sleep apnea (OSA), which are increasingly recognized as modifiable risk factors for cardiovascular disease (CVD). Aim. The aim of this narrative review was to synthesize current evidence on the association between sleep disorders and major cardiovascular outcomes and to identify the biological mechanisms underlying these relationships. Material and methods. A narrative review of the literature was conducted using PubMed, ScienceDirect, JAMA Network, OUP, and open-access repositories. Epidemiological studies, cohort studies, and meta-analyses evaluating the impact of insomnia, sleep-disordered breathing, and circadian rhythm disturbances on hypertension, coronary artery disease, heart failure, arrhythmias, and stroke were analyzed. Results. The reviewed evidence demonstrates that insomnia and obstructive sleep apnea are consistently associated with an increased risk of cardiovascular diseases, particularly hypertension, atrial fibrillation, coronary artery disease, heart failure, and stroke. The underlying mechanisms include sympathetic nervous system overactivation, oxidative stress, systemic inflammation, endothelial dysfunction, and dysregulation of glucose and lipid metabolism. Conclusions. Sleep disorders have great effects on the cardiovascular system and should be considered independent, modifiable risk factors for CVD. Early diagnosis and treatment of sleep disorders may play a crucial role in cardiovascular disease prevention and risk reduction.

  • Open Access

    INTERACTIONS BETWEEN GUT MICROBIOTA AND DEPRESSIVE AND ANXIETY DISORDERS: A COMPREHENSIVE REVIEW

    by Natalia Maria Leśniak, Klaudia Martyna Patrzykąt, Anna Maria Zakrzewska, Aleksander Midera, Julia Aleksandra Leśniak, Michał Borowski, Klaudia Elżbieta Niwińska, Julia Agnieszka Michalak, Monika Augustyn, Kinga Popielarska, et al.

    Background. Depressive and anxiety disorders are major challenges in modern medicine and are increasingly linked to gut dysbiosis. Evidence indicates that affected patients often exhibit reduced microbial diversity, lower levels of SCFA-producing bacteria, and increased pro-inflammatory taxa. Proposed mechanisms include altered SCFA production, neurotransmitter modulation, vagus nerve signaling, immune activation, HPA axis dysregulation, and impaired gut and blood–brain barrier integrity Aim. This review summarizes current evidence on the gut-brain axis and how it impacts mood disorders. Material and methods. The review analyzed English-language studies published between 2015 and 2025 using PubMed, SpringerLink, and Elsevier, focusing primarily on human research examining the gut microbiota, gut–brain axis, and their association with depressive and anxiety disorders. Results. The review highlights the potential of microbiota-based therapies for mood disorders. Probiotics, especially psychobiotic strains, show the most consistent benefits in reducing depressive and anxiety symptoms, while evidence for prebiotics and dietary interventions remains limited. Current studies are constrained by methodological heterogeneity, small sample sizes, and short intervention durations. Conclusions. Overall, accumulating data support the gut microbiota as a significant contributor to the development and modulation of depressive and anxiety disorders. While definitive clinical recommendations cannot yet be made, microbiota modulation represents a promising avenue for future integrative treatment approaches and warrants further rigorous investigation.

  • Open Access

    Challenges in the Clinical Management of Fetal Alcohol Spectrum Disorders (FASD): An Updated Review

    by Julia Bajorek, Monika Augustyn, Michał Żabicki, Agata Kes, Sylwia KęDzierska

    Background: Fetal Alcohol Spectrum Disorder (FASD) remains one of the leading preventable causes of developmental disabilities and intellectual impairment worldwide. Despite its high prevalence, especially in the European region, it is frequently underdiagnosed or misidentified due to its complex clinical presentation and phenotypic overlap with other neurodevelopmental conditions. Aim: The aim of this paper is to provide a comprehensive review of the current literature on fetal alcohol spectrum disorders (FASD), with particular emphasis on neurobiological mechanisms, diagnostic challenges and contemporary therapeutic strategies. The paper aims to systematise knowledge about clinical differences within the spectrum and to identify key factors influencing patient prognosis. Material and Methods: The PubMed, Google Scholar and Scopus databases were analysed using the keywords: ‘FASD’, ‘fetal alcohol syndrome’, ‘pathophysiology’, “diagnosis” and ‘intervention’. The literature search was updated in January 2026 to include the most recent clinical guidelines and neurodevelopmental research. Twenty-five English-language bibliographic items were included in the review, including meta-analyses, systematic reviews and current clinical guidelines. Results: The analysis showed that prenatal alcohol exposure leads to permanent structural changes in the brain through oxidative stress and epigenetic disorders, resulting in profound deficits in executive functions. It was found that standardised coding systems significantly increase the accuracy of differential diagnosis in relation to ADHD and other neurodevelopmental disorders. Conclusions: Early identification of disorders and the implementation of multidisciplinary support before the age of 6 are crucial for minimising the secondary effects of FASD. Total abstinence by pregnant women remains the only effective method of prevention, requiring ongoing public education.

  • Open Access

    The Impact of GLP-1 Analogues and Tirzepatide on Female Fertility: Mechanisms, Clinical Evidence, and Implications

    by Klaudia Elżbieta Niwińska, Michał Borowski, Julia Aleksandra Leśniak, Natalia Maria Leśniak, Klaudia Martyna Patrzykąt, Anna Maria Zakrzewska, Kinga Popielarska, Julia Agnieszka Michalak, Monika Augustyn, Aleksander Midera

    Obesity impairs female fertility through metabolic, endocrine and inflammatory pathways that disrupt ovulation, reduce oocyte competence and impair endometrial receptivity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have become highly effective therapies for weight management and metabolic optimisation, raising interest in their potential reproductive benefits. This narrative review synthesises current mechanistic and clinical evidence on how GLP-1 receptor agonists and tirzepatide may influence reproductive function in women of reproductive age. A literature search was conducted using PubMed, Scopus and Web of Science for peer-reviewed human studies and major reviews published up to December 2025 that evaluated metabolic, endocrine or reproductive outcomes. Available evidence suggests that GLP-1 signalling may influence the hypothalamic–pituitary–ovarian axis, adipokine pathways, oocyte mitochondrial function and endometrial gene expression. Clinical studies indicate that liraglutide and semaglutide improve body weight, insulin resistance and hyperandrogenism, leading to restoration of menstrual regularity and increased ovulation rates, with some reports of improved spontaneous conception and assisted reproduction outcomes. Tirzepatide provides greater metabolic benefits, although fertility-specific data remain limited. Overall, GLP-1–based therapies act primarily as metabolic optimisers that may secondarily enhance fertility, while evidence for direct reproductive effects and periconceptional safety remains insufficient.